Market Cap
$100.6B
SNY
Sanofi
$39.79 ▼ -2.15%
Prev close $40.67Market cap$100.6B
12-mo target$53.72 (+35.0%)
19 New Institutional Positions31 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SNY right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Inst. Holders
50 funds
Inst. Value
$6.4B
Inst. Activity
19 buys / 31 sells
SEC Reports
9
Price chart 30d -10.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: SNY — 55.8% short (1.5M / 2.7M)
Short: 1,490,905 | Exempt: 2,918 | TRF Vol: 2,672,408 | Short Ratio: 55.8% | Off-exchange volume (da
Sep 18, 2026 Event
RIFADIN IV
Unavailable: Discontinuation of the manufacture of the drug (Discontinuation of the manufacture of t
Sep 7, 2026 Event
Sep 2, 2026 SEC Commission approves €400 million German State aid to enhance insulin supply resilience
European Commission Press release Brussels, 08 Sep 2026 The European Commission has approved, under
The District of Oregon adopted a magistrate judge's recommendation and dismissed with prejudice a lawsuit against Sanofi
COURT-RULING — Impact 2/10
Sanofi won dismissal with prejudice of a product liability lawsuit over its drug Rezurock (belumosudil). The court grant
COURT-RULING — Impact 4/10
Sanofi lost a discovery dispute in a pending antitrust class action over alleged coordinated retraction of hospital disc
COURT-RULING — Impact 2/10
Jun 30, 2026 Inst.
BARROW HANLEY MEWHINNEY & — TRIM
2,680,973 shares ($114.4M)
Jun 30, 2026 Inst.
BALYASNY ASSET MANAGEMENT L.P. — DOUBLED
2,405,640 shares ($102.6M)
Analyst ratings buy % -20.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jan 16, 2026 | UBS | DOWNGRADE | Neutral | 55% |
| Jan 6, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Dec 9, 2025 | Guggenheim | DOWNGRADE | Neutral | 52% |
| Dec 8, 2025 | JP Morgan | DOWNGRADE | Neutral | 55% |
| Sep 8, 2025 | Morgan Stanley | UPGRADE | Overweight | 55% |
| Sep 2, 2025 | Deutsche Bank | UPGRADE | Buy | 58% |
| Aug 8, 2025 | JP Morgan | UPGRADE | Overweight | 55% |
| Mar 21, 2025 | Goldman Sachs | INITIATE | Neutral | 54% |
| Jul 26, 2024 | Argus Research | MAINTAIN | Buy | 54% |
| Jan 23, 2024 | Morgan Stanley | INITIATE | Equal-Weight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 10 | 12 | 1 | 0 | 57% | |
| Aug 1, 2026 | 7 | 10 | 12 | 1 | 0 | 57% | |
| Jul 1, 2026 | 7 | 9 | 12 | 1 | 0 | 55% | |
| Jun 1, 2026 | 7 | 9 | 12 | 1 | 0 | 55% | |
| May 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Apr 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Mar 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Feb 1, 2026 | 8 | 11 | 10 | 1 | 0 | 63% |
Price targets
Where 9 covering analysts think SNY trades over the next 12 months.
$53.72 +35.0% upside Strong Buy
Current$39.80 Low$45.00 Median$54.50 High$63.00 9 analysts
$45.00$63.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 4 bullish, 1 bearish, 1 mixed, 3 neutral · avg impact 4.2/10.
NEUTRALCOURT-RULING2/10
The District of Oregon adopted a magistrate judge's recommendation and dismissed with prejudice a la
Sep 2, 2026
BULLISHCOURT-RULING4/10
Sanofi won dismissal with prejudice of a product liability lawsuit over its drug Rezurock (belumosud
Aug 19, 2026
NEUTRALCOURT-RULING2/10
Sanofi lost a discovery dispute in a pending antitrust class action over alleged coordinated retract
Aug 14, 2026
BULLISHCOURT-RULING5/10
The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend patent claims in three IP
Aug 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Phase Phase 2 — TERMINATED
Oct 2, 2026
Clinical Trial
Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)
Phase Phase 2 — COMPLETED
Oct 1, 2026
short_volume
Short Volume: SNY — 55.8% short (1.5M / 2.7M)
Short: 1,490,905 | Exempt: 2,918 | TRF Vol: 2,672,408 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
Clinical Trial
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Phase Phase 3 — COMPLETED
Sep 30, 2026
clinical_trial_readout
Results Pending: Fitusiran (Phase 3) — Completed 16d ago
Trial: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.56 | $1.54–$1.58 | -8.0% | +1.0% | 1↑ 0↓ | $13.2B | 2 |
| Next Q | $1.12 | $1.07–$1.17 | 22.6% | +4.0% | 1↑ 0↓ | $12.5B | 2 |
| Current FY | $5.02 | $4.93–$5.15 | 7.4% | +0.6% | 2↑ 0↓ | $47.6B | 6 |
| Next FY | $5.40 | $5.19–$5.59 | 7.7% | +0.4% | 3↑ 0↓ | $50.6B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.557 | — |
| 7d ago | $1.542 | +0.015 |
| 30d ago | $1.542 | +0.015 |
| 60d ago | $1.596 | -0.038 |
| 90d ago | $1.647 | -0.090 |
Institutional ownership
Which big funds own SNY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $6.4B total value (148,976,195 shares) as of 2026-Q2. Top holders: NOMURA, DODGE, MORGAN. Net selling activity: 31 institutions trimmed/exited vs 19 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| DODGE & COX | 28,088,274 | $1.2B | 18.8% | — |
| MORGAN STANLEY | 10,702,527 | $456.6M | 7.2% | — |
| Fisher Asset Management, LLC | 10,627,088 | $453.4M | 7.1% | — |
| BANK OF AMERICA CORP /DE/ | 8,008,572 | $341.6M | 5.4% | — |
| Invesco Ltd. | 6,798,961 | $290.0M | 4.6% | — |
| JPMORGAN CHASE & CO | 6,573,682 | $285.5M | 4.5% | — |
| BRANDES INVESTMENT PARTNERS, LP | 4,136,417 | $176.5M | 2.8% | — |
| FEDERATED HERMES, INC. | 3,849,802 | $164.2M | 2.6% | — |
| Boston Partners | 3,844,844 | $164.0M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BARROW HANLEY MEWHINNEY & STRAUSS LLC | TRIM | 5,887,466 | 2,680,973 | -54.5% | $114.4M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 833,780 | 2,405,640 | +188.5% | $102.6M |
| BlackRock, Inc. | TRIM | 3,183,600 | 1,936,502 | -39.2% | $82.6M |
| UBS Group AG | ADD | 983,846 | 1,693,442 | +72.1% | $72.2M |
| NORTHERN TRUST CORP | TRIM | 2,277,939 | 1,690,344 | -25.8% | $72.1M |
| VAN ECK ASSOCIATES CORP | TRIM | 1,297,714 | 877,020 | -32.4% | $37.4M |
| Federation des caisses Desjardins du Quebec | DOUBLED | 403,774 | 873,273 | +116.3% | $37.3M |
| Point72 Asset Management, L.P. | NEW | — | 820,078 | — | $35.0M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 464,569 | 637,703 | +37.3% | $27.2M |
| Qube Research & Technologies Ltd | NEW | — | 634,794 | — | $27.1M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SNY.
Shares short
9,297,583
Settlement Sep 15, 2026
Change vs prior
+12.9%
Semi-monthly cycle
Days to cover
4.3
At avg daily volume
Of shares outstanding
≈0.4%
Estimate — not % of float
All SNY filing & press-release reports (9)
- COURT-RULING reportSep 2, 2026
- COURT-RULING reportAug 19, 2026
- COURT-RULING reportAug 14, 2026
- COURT-RULING reportAug 1, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 27, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 7, 2026
- COURT-RULING reportMay 10, 2026